Skip to main navigation Skip to search Skip to main content

Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

  • Benedito A. Carneiro
  • , Ludimila Cavalcante
  • , Devalingam Mahalingam
  • , Anwaar Saeed
  • , Howard Safran
  • , Wen Wee Ma
  • , Andrew L. Coveler
  • , Steven Powell
  • , Bruno Bastos
  • , Elizabeth Davis
  • , Vaibhav Sahai
  • , William Mikrut
  • , James Longstreth
  • , Sheri Smith
  • , Taylor Weisskittel
  • , Hu Li
  • , Brittany A. Borden
  • , R. Donald Harvey
  • , Solmaz Sahebjam
  • , Andres Cervantes
    • Austin Koukol, Andrew P. Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J. Giles, Pamela Munster
  • Brown University
  • Novant Health Cancer Institute
  • Northwestern University Feinberg School of Medicine
  • University of Pittsburgh Medical Center
  • Cleveland Clinic Foundation
  • Fred Hutchinson Cancer Center
  • University of South Dakota
  • Miami Cancer Institute at Baptist Health
  • Vanderbilt University Medical Center
  • University of Michigan, Ann Arbor
  • Vantage Data Designs
  • Long-streth & Associates
  • Courante Oncology
  • Mayo Clinic Cancer Center
  • Emory University
  • Johns Hopkins University
  • University of Valencia
  • Actuate Therapeutics
  • The Netherlands Cancer Institute
  • Medical College of Wisconsin
  • Developmental Therapeutics LLC
  • University of California San Francisco

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

15 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3b Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science